LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A ‘REAL-LIFE’ STUDYXavier Thomas, Gilles Salles, Sophie Ducastelle et al.|Mediterranean Journal of Hematology and Infectious Diseases|2020Cited by 5
Dynamics of Oligoclonal Hematopoiesis in Severe Aplastic Anemia Patients Undergoing Immunosuppressive Treatment: Longitudinal Somatic Mutation Analysis from the EBMT Race TrialD Kaya, Ghulam Mufti, Riley Cook et al.|Blood|2024Cited by 2
Eltrombopag Added to Standard Immunosuppressive Treatment Improves Long-Term Outcomes As Front-Line Therapy for Severe Aplastic Anemia: Final 2-Year Analysis of EBMT-Saawp Race StudyAntonio M. Risitano, Régis Peffault de Latour, S. Iacobelli et al.|Blood|2024Cited by 1
Deep immune signature of immune-mediated aplastic anemia patients shows distinct subsets of regulatory T cells associated with response to treatment: Results from the phase 3, randomized EBMT race clinical trialSıla Gerlevik, Ghulam Mufti, Giorgio Napolitani et al.|Blood|2025Cited by 0
<scp>Eltrombopag</scp> Added to Standard Immunosuppressive Treatment as Front‐Line Therapy for Severe Aplastic Anemia: Long‐Term Outcomes of the Phase‐3 Randomized Superiority <scp>EBMT</scp> ‐ <scp>SAAWP RACE</scp> StudyAntonio M. Risitano, Ghulam J. Mufti, Simona Iacobelli et al.|American Journal of Hematology|2026Cited by 0